Target- |
MechanismApoptosis stimulants |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismProstaglandin agonists |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Determine the Efficacy, the Duration of Action, and Safety of Latanoprost in Patients With Menière's Disease
The purpose of the study is to evaluate the dose regimen, efficacy and safety of latanoprost for the treatment of Menière's disease.
A randomized, double-blind, placebo-controlled, parallel group study to determine the efficacy, the duration of action, and safety of latanoprost in patients with Menière’s disease
N/A - Topical treatment of plaque psoriasis with three doses of JB991.
100 Clinical Results associated with Synphora AB
0 Patents (Medical) associated with Synphora AB
100 Deals associated with Synphora AB
100 Translational Medicine associated with Synphora AB